Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
Condition(s):Myeloproliferative Disorder; Aquagenic PruritusLast Updated:June 11, 2021Unknown status
Hide Studies Not Open or Pending
Condition(s):Myeloproliferative Disorder; Aquagenic PruritusLast Updated:June 11, 2021Unknown status
Condition(s):Placebo Effect; Placebo Drug InteractionLast Updated:March 3, 2017Completed
Condition(s):HealthyLast Updated:October 20, 2006Terminated
Condition(s):Substance-Related DisordersLast Updated:June 5, 2017Completed
Condition(s):PainLast Updated:July 23, 2014Completed
Condition(s):PainLast Updated:January 22, 2021Terminated
Condition(s):Anxiety in Those Patients With Anorexia Nervosa; Eating Disorder Not Otherwise Specified, BMI (<=18)Last Updated:November 15, 2016Withdrawn
Condition(s):Healthy VolunteersLast Updated:November 6, 2013Completed
Condition(s):Agitation on Recovery From SedationLast Updated:December 6, 2019Unknown status
Condition(s):Effect of Drug; AnxietyLast Updated:December 27, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.